
I-Mab IMAB
Quartalsbericht 2025-Q4
hinzugefügt 11.04.2026
I-Mab ROA 2011-2026 | IMAB
ROA Jährlich I-Mab
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 7.43 | -83.56 | -16.95 | -29.09 | - | - | - | - | - | - |
Alle Zahlen in CNY-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.43 | -83.56 | -30.54 |
ROA anderer Aktien in der Pharmaeinzelhändler
| Name | ROA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
BioNTech SE
BNTX
|
65.02 | $ 97.23 | 1.81 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-27.33 | $ 8.47 | 5.94 % | $ 83.7 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.63 | -2.42 % | $ 8.73 B | ||
|
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Esperion Therapeutics
ESPR
|
-4.87 | $ 2.22 | 2.07 % | $ 461 M | ||
|
Evogene Ltd.
EVGN
|
-39.9 | $ 0.78 | -4.39 % | $ 27.9 M | ||
|
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | ||
|
Genmab A/S
GMAB
|
22.5 | $ 28.2 | -0.18 % | $ 18 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.06 | 3.39 % | $ 984 M | ||
|
Grifols, S.A.
GRFS
|
1.38 | $ 8.35 | 1.64 % | $ 6.83 B | ||
|
GT Biopharma
GTBP
|
-349.79 | $ 0.38 | 2.93 % | $ 2.1 M | ||
|
Halozyme Therapeutics
HALO
|
12.55 | $ 66.57 | -1.85 % | $ 7.98 B | ||
|
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
Harmony Biosciences Holdings
HRMY
|
12.48 | $ 28.98 | 0.31 % | $ 1.67 B | ||
|
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.44 | 2.86 % | $ 370 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.99 | 2.4 % | $ 4.92 M | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.2 | 2.82 % | $ 449 M | ||
|
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 23.99 | -0.93 % | $ 3.05 B | ||
|
Immatics N.V.
IMTX
|
1.73 | $ 10.81 | 3.64 % | $ 680 M | ||
|
Incyte Corporation
INCY
|
18.49 | $ 94.08 | -2.07 % | $ 18.4 B | ||
|
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-44.38 | $ 32.41 | 0.51 % | $ 2.15 B | ||
|
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.47 | -1.68 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | ||
|
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.48 | 4.61 % | $ 235 M | ||
|
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M |